Loading...
Conditional Survival in Patients with Advanced Renal Cell Carcinoma Treated with Nivolumab
BACKGROUND: Nivolumab is approved for the treatment of advanced renal cell carcinoma (RCC). However, traditional overall survival (OS) or progression-free survival (PFS) do not reflect patient prognosis after initial management. Therefore, this study aimed to evaluate conditional overall survival (C...
Na minha lista:
| Udgivet i: | Med Sci Monit |
|---|---|
| Main Authors: | , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
International Scientific Literature, Inc.
2019
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6738006/ https://ncbi.nlm.nih.gov/pubmed/31469816 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.12659/MSM.916984 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|